Skip to main content
. 2022 Sep 29;12(10):920. doi: 10.3390/metabo12100920

Table 1.

Details of SUM METAB (TBW + URINE) in control (n = 69) and nitisinone-treated (n = 69) groups in the combined female and male group.

Age (Years) Weight (kg) SUM METAB (µmol/L) Change SUM METAB % cAKUSSI mAKUSSI OCH SC
Control group
V1 47.6 ± 10.1 74.1 ± 15.5 42,716 ± 15,212 80.4 ± 33.3 54.0 ± 24.9 * 18.0 ± 10.9
V2 48.1 ± 10.0 74.7 ± 15.6 38,829 ± 19,257 −9.1 ± 36.5
V3 48.8 ± 10.0 74.3 ± 15.6 36,485 ± 12,065 −9.0 ± 37.0 79.2 ± 34.8 54.8 ± 25.6 17.8 ± 10.9
V4 49.8 ± 10.1 76.0 ± 15.7 37,503 ± 10,428 −11.8 ± 28.2 83.1 ± 33.9 57.2 ± 26.1 17.8 ± 10.7
V5 50.6 ± 10.1 74.9 ± 14.6 40,699 ± 13,268 0.9 ± 47.3 90.1 ± 37.2 63.4 ± 30.3 19.4 ± 10.7
V6 51.6 ± 10.1 73.8 ± 15.0 41,020 ± 11,724 0.2 ± 38.6 95.7 ± 36.4 67.0 ± 29.9 20.3 ± 11.2
Nitisinone group
V1 49.0 ± 11.3 74.8 ± 14.8 42,268 ± 14,177 **** 86.9 ± 34.6 56.6 ± 27.2 21.4 ± 10.7
V2 49.2 ± 11.3 75.7 ± 15.1 91,145 ± 29,629 131 ± 106
V3 49.8 ± 11.3 78.1 ± 15.0 82,204 ± 20,743 110 ± 86 84.2 ± 34.0 57.2 ± 27.3 20.9 ± 11.1
V4 50.8 ± 11.3 78.6 ± 15.3 82,343 ± 21,724 110 ± 85 91.1 ± 35.6 62.1 ± 28.3 21.1 ± 10.6
V5 51.3 ± 11.3 78.6 ± 15.9 84,610 ± 22,801 111 ± 64 88.8 ± 38.8 61.2 ± 31.1 20.2 ± 10.8
V6 52.6 ± 11.4 78.4 ± 16.1 80,874 ± 24,976 105 ± 65 94.8 ± 37.3 66.4 ± 31.2 20.3 ± 10.8

V1–V6 refers to visits to study sites at baseline, 3, 12, 24, 36 and 48 months; values are shown as Mean ± SD; statistical comparisons within control or nitisinone group denotes whether there were differences within the group across visits and to what degree indicated as: p = 0.058; * <0.05; ** <0.01; *** <0.001; **** <0.0001.